Quick Answer
LIGAND PHARMACEUTICALS INC reported Net Income Loss of $124.45 million for the year ending 2025.
- LIGAND PHARMACEUTICALS INC showed an increase of +3,186.6% in Net Income Loss from 2024 to 2025.
- This data is from LIGAND PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2016: -$5.76 million | Q3 2016: $1.05 million | Q4 2016: -$3.13 million | Q1 2017: $45.28 million | Q2 2017: $73.16 million | Q3 2017: $67.36 million | Q4 2017: -$42.48 million | Q1 2018: $45.28 million | Q2 2018: $73.16 million | Q3 2018: $67.36 million | Q4 2018: -$42.48 million | Q1 2019: $666.34 million | Q2 2019: -$14.42 million | Q3 2019: -$15.25 million | Q4 2019: -$7.37 million | Q1 2020: -$24.13 million | Q2 2020: $22.09 million | Q3 2020: -$6.70 million | Q4 2020: $5.76 million | Q1 2021: $18.11 million | Q2 2021: $30.73 million | Q3 2021: $13.72 million | Q4 2021: -$5.42 million | Q1 2022: -$15.39 million | Q2 2022: -$895.0 thousand | Q3 2022: $404.0 thousand | Q4 2022: -$17.49 million | Q1 2023: $41.95 million | Q2 2023: $2.29 million | Q3 2023: -$10.27 million | Q1 2024: $86.14 million | Q2 2024: -$51.91 million | Q3 2024: -$7.17 million | Q1 2025: -$42.45 million | Q2 2025: $4.85 million | Q3 2025: $117.27 million.
- Over the full 17 years of available data (2009 to 2025), LIGAND PHARMACEUTICALS INC's Net Income Loss has grown by 6,488.8%.
- Historical annual values: Fiscal year 2025: $124.45 million | Fiscal year 2024: -$4.03 million | Fiscal year 2023: $52.15 million | Fiscal year 2022: -$33.36 million | Fiscal year 2021: $57.14 million | Fiscal year 2020: -$2.99 million | Fiscal year 2019: $629.30 million | Fiscal year 2018: $143.32 million | Fiscal year 2017: $12.56 million | Fiscal year 2016: -$1.64 million | Fiscal year 2015: $229.82 million | Fiscal year 2014: $12.02 million | Fiscal year 2013: $11.42 million | Fiscal year 2012: -$527.0 thousand | Fiscal year 2011: $9.72 million | Fiscal year 2010: -$10.37 million | Fiscal year 2009: -$1.95 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: